Cargando…
The use of nebulized pharmacotherapies during the COVID-19 pandemic
Coronavirus disease 2019 (COVID-19), caused by the highly contagious novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a worldwide pandemic and currently represents a major public health issue. COVID-19 has highlighted the need for clear and accurate guidance on the...
Autores principales: | Sethi, Sanjay, Barjaktarevic, Igor Z., Tashkin, Donald P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675890/ https://www.ncbi.nlm.nih.gov/pubmed/33167796 http://dx.doi.org/10.1177/1753466620954366 |
Ejemplares similares
-
Nebulized Therapies in COPD: Past, Present, and the Future
por: Barjaktarevic, Igor Z, et al.
Publicado: (2020) -
A review of nebulized drug delivery in COPD
por: Tashkin, Donald P
Publicado: (2016) -
Positioning new pharmacotherapies for COPD
por: Barjaktarevic, Igor Z, et al.
Publicado: (2015) -
Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021) -
Marijuana Use as a Risk Factor for Chronic Obstructive Pulmonary Disease: Not There Yet
por: Tashkin, Donald P., et al.
Publicado: (2023)